SudiptoMukherjeeMDPhD, MPH

PubMed

• Treatment patterns and outcomes with luspatercept in patients with lower-risk myelodysplastic syndromes: A retrospective US cohort analysis.
  Brown-Bickerstaff, C., Falkenstein, A., Makinde, A., Bland, E., Laney, J., Garretson, M., Huggar, D., McBride, A., Mukherjee, S.> ;Hemasphere. 2024 Jan 1
• A rare case of Philadelphia-positive (P210BCR-ABL1) T-cell acute lymphoblastic leukemia/lymphoma associated with minimal residual disease persistence after intensive c...
  Shruti Shah, Rahul Mishra, Rupayan Kundu, Sudipto Mukherjee, Abhay Singh> ;Leukemia Research Reports. 2024 Jan 1
• Symptom burden in patients with idiopathic multicentric Castleman disease and its impact on daily life: an international patient and caregiver survey.
  Sudipto Mukherjee, Francis Shupo, Grace Wayi-Wayi, Natasa Zibelnik, Emily Jones, Nicola Mason, Matthew Franklin, John Brazier> ;Eclinicalmedicine. 2023 Oct 1
• Cancer burden in women with HIV on Medicaid: A nationwide analysis.
  Guangjin Zhou, Siran M Koroukian, Suparna M Navale, Nicholas K Schiltz, Uriel Kim, Johnie Rose, Gregory S Cooper, Scott E Moore, Laura J Mintz, Ann K Avery, Sudipto Mu...> ;Women's Health. 2023 May 15
• Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes.
  Sudipto Mukherjee, Weichuan Dong, Nicholas K Schiltz, Kurt C Stange, Jennifer Cullen, Aaron T Gerds, Hetty E Carraway, Abhay Singh, Anjali S Advani, Mikkael A Sekeres,...> ;The Oncologist. 2023 Oct 3
• Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims a...
  Sudipto Mukherjee, Karan Kanhai, David Kauffman, Rabecka Martin, Jeremy S Paige, Anirvan Ghosh, Hannah Kannan, Francis Shupo, David C Fajgenbaum> ;Leukemia. 2023 Jan 1
• 2 citations
  Incidence, Clinical Features, and Outcomes of Langerhans Cell Histiocytosis in the United States.
  Ilia N Buhtoiarov, Sudipto Mukherjee, Tomas Radivoyevitch> ;Journal of Pediatric Hematology/oncology. 2022 Oct 1
• 2 citations
  Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis.
  Sudipto Mukherjee, Karan Kanhai, David Kauffman, Rabecka Martin, Jeremy S Paige, Anirvan Ghosh, Hannah Kannan, Francis Shupo, David C Fajgenbaum> ;Leukemia. 2022 Oct 1
• 5 citations
  Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes.
  Sanghee Hong, Lisa Rybicki, Carmelo Gurnari, Simona Pagliuca, Aiwen Zhang, Dawn Thomas, Valeria Visconte, Jibran Durrani, Ronald M Sobecks, Matt Kalaycio, Aaron T Gerd...> ;Bone Marrow Transplantation. 2022 Oct 1
• 2 citations
  Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.
  Mohammad Ebad Ur Rehman, Asmi Chattaraj, Karun Neupane, Abdul Rafae, Sajeel Saeed, Jawad Basit, Atif Ibrahim, Jack Khouri, Sudipto Mukherjee, Faiz Anwer> ;European Journal of Haematology. 2022 Oct 1
• 8 citations
  Excess cancer prevalence in men with HIV: A nationwide analysis of Medicaid data.
  Siran M Koroukian, Guangjin Zhou, Suparna M Navale, Nicholas K Schiltz, Uriel Kim, Johnie Rose, Gregory S Cooper, Scott Emory Moore, Laura J Mintz, Ann K Avery, Sudipt...> ;Cancer. 2022 May 15
• 2 citations
  Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review.
  Qiukui Hao, Farid Foroutan, Mi Ah Han, Tahira Devji, Fernando Kenji Nampo, Sudipto Mukherjee, Shabbir M H Alibhai, Ashley Rosko, Mikkael A Sekeres, Gordon H Guyatt, Ro...> ;Plos One. 2022 Jan 1
• 8 citations
  A geno-clinical decision model for the diagnosis of myelodysplastic syndromes.
  Nathan Radakovich, Manja Meggendorfer, Luca Malcovati, C. Beau Hilton, Mikkael A. Sekeres, Jacob Shreve, Yazan Rouphail, Wencke Walter, Stephan Hutter, Anna Gallì, Sar...> ;Blood Advances. 2021 Nov 9
• 16 citations
  Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6 directed therapy.
  Sudipto Mukherjee, Rabecka Martin, Brenda Sande, Jeremy Paige, David C. Fajgenbaum> ;Blood Advances. 2021 Sep 17
• 34 citations
  Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes
  Aziz Nazha, Rami S. Komrokji, Manja Meggendorfer, Xuefei Jia, Nathan Radakovich, Jacob Shreve, C. Beau Hilton, Yasunubo Nagata, Betty K. Hamilton, Sudipto Mukherjee, N...> ;Journal of Clinical Oncology. 2021 Aug 18
• Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
  Mohamed L Sorror, Barry E Storer, Amir T Fathi, Andrew Brunner, Aaron T Gerds, Mikkael A Sekeres, Sudipto Mukherjee, Bruno C Medeiros, Eunice S Wang, Pankit Vachhani, ...> ;Blood. 2021 Aug 5
• Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.
  Mohamed L. Sorror, Barry E. Storer, Amir T. Fathi, Andrew M. Brunner, Aaron T. Gerds, Mikkael A. Sekeres, Sudipto Mukherjee, Bruno C. Medeiros, Eunice S. Wang, Pankit ...> ;Blood. 2021 Apr 28
• 1 citations
  Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review
  Yaping Chang, Gordon H. Guyatt, Trevor Teich, Jamie L. Dawdy, Shaneela Shahid, Jessica K. Altman, Richard Stone, Mikkael A. Sekeres, Sudipto Mukherjee, Thomas W. LeBla...> ;Plos One. 2021 Mar 30
• 5 citations
  A case of hypereosinophilic syndrome with STAT5b N642H mutation
  Feihong Ding, C.-P. Wu, Yun Li, Sudipto Mukherjee, Subha Ghosh, A Valeria Arrossi, Sudhir Krishnan> ;Oxford Medical Case Reports. 2021 Jan 1
• 1 citations
  Rosai-Dorfman Disease of the Right Ventricular Outflow Tract: Role of Multimodality Imaging.
  Tom Kai Ming Wang, Sudipto Mukherjee, Carmela D. Tan, Dale R. Shepard, Gösta B. Pettersson, Milind Y. Desai> ;Circulation. Cardiovascular Imaging. 2020 Nov 26
• 5 citations
  Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia
  Vera Adema, Jack Khouri, Ying Ni, Heesun J. Rogers, Cassandra M Kerr, Hassan Awada, Yasunobu Nagata, Teodora Kuzmanovic, Anjali S. Advani, Aaron T. Gerds, Sudipto Mukh...> ;Leukemia & Lymphoma. 2021 Feb 23
• 16 citations
  Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
  David C. Fajgenbaum, David Wu, Aaron M. Goodman, Raymond S.M. Wong, Amy Chadburn, Sunita D. Nasta, Gordan Srkalovic, Sudipto Mukherjee, Heather A. Leitch, Raj Jayantha...> ;American Journal of Hematology. 2020 Sep 25
• 26 citations
  Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.
  Elizabeth A. Griffiths, Laura M Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter T. Curtin, Mark B. Geyer, Ivana Gojo, Avyakta Kallam, Wajih Zaheer Kidwai, Dwigh...> ;Journal of the National Comprehensive Cancer Network. 2020 Sep 1
• 98 citations
  American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
  Mikkael A. Sekeres, Gordon H. Guyatt, Gregory A. Abel, Shabbir M.H. Alibhai, Jessica K. Altman, Rena Buckstein, Hannah Choe, Pinkal Desai, Harry P. Erba, Christopher S...> ;Blood Advances. 2020 Aug 11
• 4 citations
  Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes
  Guillermo Garcia-Manero, Naveen Pemmaraju, Yesid Alvarado, Kiran Naqvi, Farhad Ravandi, Elias Jabbour, Ricardo De Lumpa, Hagop M. Kantarjian, Anjali S. Advani, Sudipto...> ;Leukemia & Lymphoma. 2020 Apr 7
• Join now to see all

Journal Articles

• International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease  
  Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood

Abstracts/Posters

• Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoie...
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Determinants of Fitness for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving I...
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and My...
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features
  Sudipto Mukherjee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Real-World Treatment Patterns and Transfusion Burden Among US Patients with Newly Diagnosed Myelodysplastic Syndromes (MDS) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Population Risks of Developing Myeloid Malignancies 
  60th American Society of Hematology Annual Meeting - 12/2/2018
• Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of CancerClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all